Tech Center 1600 • Art Units: 1649 1675
This examiner grants 49% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 19358181 | METHODS OF TREATING TUMORS | Non-Final OA | Halozyme, Inc. |
| 17482650 | Stable Formulations of Programmed Death Receptor 1 (PD-1) Antibodies and Hyaluronidase Variants and Fragments Thereof and Methods of Use Thereof | Final Rejection | Merck Sharp & Dohme LLC |
| 17041783 | SUBCUTANEOUS DOSING OF ANTI-CD38 ANTIBODIES | Non-Final OA | TAKEDA PHARMACEUTICAL COMPANY LIMITED |
| 17779499 | COMBINATION THERAPY FOR HEAD AND NECK CANCER | Final Rejection | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 17774125 | METHODS FOR TREATING LEUKEMIA | Non-Final OA | AMGEN INC. |
| 17112198 | METHODS FOR TREATING COPD BY ADMINISTERING AN IL-33 ANTAGONIST | Final Rejection | Regeneron Pharmaceuticals, Inc. |
| 18026746 | METHODS OF TREATING AN INDIVIDUAL THAT HAS FAILED AN ANTI-PD-1/ANTI-PD-L1 THERAPY | Non-Final OA | Dana-Farber Cancer Institute, Inc. |
| 16982333 | COMPOSITIONS AND METHODS FOR CANCER TREATMENT | Non-Final OA | Dana-Farber Cancer Institute, Inc. |
| 17762354 | NK ENGAGER COMPOUNDS THAT BIND VIRAL ANTIGENS AND METHODS OF USE | Final Rejection | Regents of the University of Minnesota |
| 17262667 | COMPOSITIONS AND METHODS FOR COMBATING MULTIDRUG-RESISTANT BACTERIA | Non-Final OA | University of Virginia Patent Foundation |
| 18278394 | INTERCELLULAR ADHESION MOLECULE 1 (ICAM1) ANTIBODY DRUG CONJUGATE AND USES THEREOF | Non-Final OA | Children's Medical Center Corporation |
| 17477435 | METHODS FOR TREATING MULTIPLE MYELOMA | Final Rejection | Janssen Pharmaceutica NV |
| 17776556 | Combination Therapy Based on PD-1 Signaling Inhibitors | Final Rejection | Kyoto University |
| 17622634 | MODULATION OF DENDRITIC CELL FUNCTION BY THE PHOSPHOLIPID MESSENGER LPA | Non-Final OA | Cornell University |
| 18266455 | COMPOSITIONS AND METHODS FOR TREATING CANCER | Non-Final OA | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVIC |
| 17997775 | ANTIBODY-DRUG CONJUGATE AND PREPARATION THEREOF | Final Rejection | LEPU BIOPHARMA CO., LTD. |
| 17519811 | FCRN ANTIBODIES AND METHODS OF USE THEREOF | Non-Final OA | Momenta Pharmaceuticals, Inc. |
| 18264070 | ANTIBODIES AGAINST HUMAN TSLP AND USE THEREOF | Non-Final OA | Chongqing Genrix Biopharmaceutical Co., Ltd. |
| 17258248 | Use of Immunomodulators to Control Infection and Stimulate Healing in Normal and Diabetic Wounds | Non-Final OA | Rush University Medical Center |
| 17290060 | CHIMERIC ANTIGEN RECEPTORS SPECIFIC FOR G PROTEIN-COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D (GPRC5D) | Final Rejection | Memorial Sloan Kettering Cancer Center |
| 18299453 | COMPOSITION AND METHODS OF TREATMENT USING SYNERGISTICALLY-ENHANCED SUPPLEMENTATION | Non-Final OA | Xygenyx Inc. |
| 18185848 | ANTI-CD73 ANTIBODIES AND COMPOSITIONS | Non-Final OA | LES LABORATOIRES SERVIER |
| 17910310 | APPLICATION OF IFN-y IN PREPARING ANTI-TUMOR ADJUVANT DRUG | Non-Final OA | West China Hospital of Sichuan University |
| 18016964 | USE OF INHALED INTERFERON-BETA TO IMPROVE OUTCOME IN SARS-CoV-2 INFECTED PATIENTS | Final Rejection | SYNAIRGEN RESEARCH LIMITED |
| 17999735 | ADAPTER MOLECULES TO RE-DIRECT CAR T CELLS TO AN ANTIGEN OF INTEREST | Non-Final OA | UNIVERSITY OF ZURICH |
| 18051993 | Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation | Non-Final OA | University of Leicester |
| 17996878 | ANTI-CD73-ANTI-PD-1 BISPECIFIC ANTIBODY AND USE THEREOF | Non-Final OA | Akeso Biopharma, Inc |
| 17929417 | NATURAL KILLER CELLS | Non-Final OA | NK:IO Ltd |
| 17693928 | TESTING METHODS FOR DETERMINATION OF T2R PHENOTYPE AND APPLICATIONS THEREOF | Final Rejection | Phenomune, LLC |
| 17409589 | METHODS OF TREATING CANCER | Non-Final OA | CITIUS PHARMACEUTICALS, INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy